Skip to content
ESSA Pharma
  • Our Company
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisors
    • Careers
  • Pipeline
    • Pipeline
    • Expanded Access Policy
    • Androgen Receptor
    • Aniten Compounds
    • Publications
  • News
  • Investors
    • Investor Info
    • Corporate Governance
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Investor Contact
    • Publications
    • SEC Regulatory Filings
  • Contact
ESSA PHARMA, INC. HAS BEGUN DEVELOPMENT OF A SECOND GENERATION ANITEN COMPOUND FOR THE TREATMENT OF HORMONE-DRIVEN CANCER

News

News Archives

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
Date Title
March 2, 2015

ESSA PHARMA INC. REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS

February 27, 2015

ESSA PHARMA AND BLOOM BURTON ANNOUNCE ADDITIONAL RELEASE OF SHARES FROM VOLUNTARY LOCK-UP AGREEMENT

February 25, 2015

ESSA Pharma Inc. Announces Confidential Submission of Draft Registration Statement on Form 20-F with the SEC

January 27, 2015

ESSA PHARMA INC. LISTS ON THE TSX VENTURE EXCHANGE

January 26, 2015

ESSA Pharma Inc. Reports Year-End Financial and Operating Results

January 19, 2015

ESSA Pharma Inc. Announces Closing of Private Placement Financing

December 23, 2014

ESSA Pharma Inc. Becomes Reporting Issuer and Receives Conditional Approval to Commence Trading on TSX-V Exchange

  • «
  • 1
  • …
  • 12
  • 13
  • 14
  • Home
  • Our Company
  • Executive Team
  • Board of Directors
  • Scientific Advisors
  • Careers
  • Pipeline
  • Expanded Access Policy
  • Androgen Receptor
  • Aniten Compounds
  • Publications
  • News
  • Press Releases
  • Investors
  • Corporate Governance
  • Events & Presentations
  • Financial Information
  • Stock Information
  • Analyst Coverage
  • Investor Contact
  • Contact
  • Locations & Inquiries
© ESSA Pharma, Inc. 2020. All rights reserved. Privacy Policy | Terms & Conditions | Code of Conduct